We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

128 hedge funds and large institutions have $175M invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $4.95M | Put options by funds: $1.46M

24% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 33

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

1% more funds holding

Funds holding: 127128 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

51% less capital invested

Capital invested by funds: $360M → $175M (-$185M)

Holders
128
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
3.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
41
Reduced
33
Closed
23
Calls
$4.95M
Puts
$1.46M
Net Calls
+$3.48M
Net Calls Change
+$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
TCP
126
Tourbillon Capital Partners
New York
-$5.56M -980,931 Closed
Lord, Abbett & Co
127
Lord, Abbett & Co
New Jersey
-$4.05M -714,132 Closed
MCM
128
Moore Capital Management
New York
-$3.77M -665,000 Closed
EI
129
EAM Investors
California
-$3.67M -647,686 Closed
GTC
130
Ghost Tree Capital
New York
-$3.4M -600,000 Closed
DCM
131
Driehaus Capital Management
Illinois
-$2.77M -489,127 Closed
Renaissance Technologies
132
Renaissance Technologies
New York
-$2.25M -397,600 Closed
NIP
133
Nicholas Investment Partners
California
-$2.24M -395,059 Closed
Point72 Asset Management
134
Point72 Asset Management
Connecticut
-$1.82M -320,400 Closed
ACM
135
Asymmetry Capital Management
California
-$1.72M -303,157 Closed
WRF
136
Waddell & Reed Financial
Kansas
-$1.67M -294,300 Closed
KCM
137
Kingdon Capital Management
New York
-$1.3M -229,420 Closed
Axa
138
Axa
France
-$1.25M -220,380 Closed
RFC
139
Russell Frank Company
Washington
-$1.22M -214,079 Closed
OAM
140
Oxford Asset Management
United Kingdom
-$1.1M -194,406 Closed
Squarepoint
141
Squarepoint
New York
-$377K -66,500 Closed
AL
142
Airain Ltd
Guernsey
-$374K -66,017 Closed
CCM
143
Cadence Capital Management
Massachusetts
-$365K -64,415 Closed
QSS
144
Quantitative Systematic Strategies
Florida
-$305K -53,544 Closed
SCM
145
Stevens Capital Management
Pennsylvania
-$227K -40,047 Closed
BNP Paribas Financial Markets
146
BNP Paribas Financial Markets
France
-$123K -21,764 Closed
TI
147
Trexquant Investment
Connecticut
-$89K -15,628 Closed
QT
148
Quantbot Technologies
New York
-$57K -10,064 Closed
TRCT
149
Tower Research Capital (TRC)
New York
-$21.9K -6,046 -98%
IA
150
IFP Advisors
Florida
+$11.9K +3,288 +462%

SGYP Hedge Fund Activity: Q1 2016 in Review

128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2016, worth a combined $175M — down 51% from $360M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SGYP positions and 23 closed out — a net gain of 1 holder — while 41 added to existing stakes and 33 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $7.97M. The largest seller was Citadel Advisors, cutting an estimated $7.03M.

  • 128 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2016, up from 127 in Q4 2015.
  • Funds reported $175M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2016, down 51% quarter-over-quarter.
  • 24 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2016 and 23 closed out, a net change of +1 holder.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2016 was Armistice Capital, an estimated $7.97M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2016 was Citadel Advisors, an estimated $7.03M sold.

Based on aggregated 13F filings for Q1 2016.